Invention Grant
- Patent Title: FGFR-Fc fusion proteins and the use thereof
- Patent Title (中): FGFR-Fc融合蛋白及其用途
-
Application No.: US13842345Application Date: 2013-03-15
-
Publication No.: US09273137B2Publication Date: 2016-03-01
- Inventor: Jianmin Fang , Dong Li
- Applicant: YANTAI RC BIOTECHNOLOGIES
- Applicant Address: CN Shandong
- Assignee: REMEGEN, LTD.
- Current Assignee: REMEGEN, LTD.
- Current Assignee Address: CN Shandong
- Agency: Saliwanchik, Lloyd & Eisenschenk
- Priority: CN2011101322189 20110520
- Main IPC: C07K16/22
- IPC: C07K16/22 ; C07K14/71 ; A61K47/48 ; A61K38/00 ; C07K16/28
Abstract:
The present invention belongs to the field of biotechnology and relates to the treatment of diseases, especially the treatment of FGF overexpression-related diseases. Particularly, the present invention relates to FGFR-Fc fusion proteins and the use thereof in the treatment of angiogenesis regulation-related diseases. More particularly, the present invention relates to isolated soluble FGFR-Fc fusion proteins and their applications in manufacture of the medicament for the treatment of angiogenesis regulation-related diseases.
Public/Granted literature
- US20130195864A1 FGFR-FC FUSION PROTEIN AND USE THEREOF Public/Granted day:2013-08-01
Information query
